Compare TG Therapeutics Inc (TGTX) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs United Microelectronics Corp — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while United Microelectronics Corp trades at $22.2 (market cap $54.48B). The key difference: United Microelectronics Corp is far larger — about 6.4× TG Therapeutics Inc's market cap, and United Microelectronics Corp pays a 1.84% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | UMC | |
|---|---|---|
Market Cap | $8.53B | $54.48B |
Sector | Health | Technology |
52-Week High | $59.06 | $28.02 |
52-Week Low | $26.94 | $6.76 |
Enterprise Value | $8.74B | $51.52B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
UMC trades at $21.82, up 5.06% in 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a net income margin of 32.75% and ROE of 21.03%, though revenue has moderated from 2022 peaks. Recent news highlights sales growth, AI expansion plans, and mixed analyst sentiment amid volatility in the semiconductor sector.
Outlook is positive with earnings momentum and strategic investments in silicon photonics, but risks include competitive pressures and reliance on AI spending cycles. Analysts are divided, with 26.7% buy ratings versus 53.3% hold, suggesting cautious optimism for long-term growth despite near-term overbought signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
